PDCD1 and neoplasm: The development of immune checkpoint therapies is an effective strategy to enhance anti-tumor immune responses of T-cells, for example using antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (Hodi et al., 2010) or programmed cell-death 1 (PD-1) (Robert et al., 2015).